These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 33393598)

  • 21. Investigator-Driven Randomised Controlled Trial of Cefiderocol versus Standard Therapy for Healthcare-Associated and Hospital-Acquired Gram-negative Bloodstream Infection: Study protocol (the GAME CHANGER trial): study protocol for an open-label, randomised controlled trial.
    Wright H; Harris PNA; Chatfield MD; Lye D; Henderson A; Harris-Brown T; Donaldson A; Paterson DL
    Trials; 2021 Dec; 22(1):889. PubMed ID: 34876196
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cefiderocol for Infections Caused by Multidrug-Resistant Gram-Negative Bacteria.
    Weaver K; Stallworth K; Blakely KK
    Nurs Womens Health; 2020 Oct; 24(5):377-382. PubMed ID: 32890463
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical Trials.
    Nordmann P; Shields RK; Doi Y; Takemura M; Echols R; Matsunaga Y; Yamano Y
    Microb Drug Resist; 2022 Apr; 28(4):398-407. PubMed ID: 35076335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cefiderocol (Fetroja) as a Treatment for Hospital-Acquired Pneumonia.
    Plaisance CJ; Borne GE; Daniel CP; Wagner MJ; Shelvan A; Mathew J; Ahmadzadeh S; Paladini A; Varrassi G; Shekoohi S; Kaye AD
    Cureus; 2024 Jan; 16(1):e52230. PubMed ID: 38352089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Designing A Pathogen-Focused Study To Address The High Unmet Medical Need Represented By Carbapenem-Resistant Gram-Negative Pathogens - The International, Multicenter, Randomized, Open-Label, Phase 3 CREDIBLE-CR Study.
    Bassetti M; Ariyasu M; Binkowitz B; Nagata TD; Echols RM; Matsunaga Y; Toyoizumi K; Doi Y
    Infect Drug Resist; 2019; 12():3607-3623. PubMed ID: 31819544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population Pharmacokinetic Analysis of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Healthy Subjects, Subjects with Various Degrees of Renal Function, and Patients with Complicated Urinary Tract Infection or Acute Uncomplicated Pyelonephritis.
    Kawaguchi N; Katsube T; Echols R; Wajima T
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29038272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Iron serum levels and iron homeostasis parameters in patients with nosocomial pneumonia treated with cefiderocol: post hoc analysis of the APEKS-NP study.
    Skaar EP; Echols R; Matsunaga Y; Menon A; Portsmouth S
    Eur J Clin Microbiol Infect Dis; 2022 Mar; 41(3):467-476. PubMed ID: 35025025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol.
    Bilal M; El Tabei L; Büsker S; Krauss C; Fuhr U; Taubert M
    Clin Pharmacokinet; 2021 Dec; 60(12):1495-1508. PubMed ID: 34420182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients with Pneumonia, Bloodstream Infection/Sepsis, or Complicated Urinary Tract Infection.
    Kawaguchi N; Katsube T; Echols R; Wajima T
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33257454
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical experience using cefiderocol].
    Witzke O; Brenner T
    Med Klin Intensivmed Notfmed; 2023 Mar; 118(2):149-155. PubMed ID: 35913604
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The β-Lactams Strike Back: Ceftazidime-Avibactam.
    Zasowski EJ; Rybak JM; Rybak MJ
    Pharmacotherapy; 2015 Aug; 35(8):755-70. PubMed ID: 26289307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical experience of cefiderocol.
    Fariñas MC
    Rev Esp Quimioter; 2022 Sep; 35 Suppl 2(Suppl 2):35-38. PubMed ID: 36193983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections.
    Eljaaly K; Alharbi A; Alshehri S; Ortwine JK; Pogue JM
    Drugs; 2019 Feb; 79(3):243-269. PubMed ID: 30723876
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification and pretherapy susceptibility of pathogens in patients with complicated urinary tract infection or acute pyelonephritis enrolled in a clinical study in the United States from November 2004 through April 2006.
    Peterson J; Kaul S; Khashab M; Fisher A; Kahn JB
    Clin Ther; 2007 Oct; 29(10):2215-21. PubMed ID: 18042477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
    Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF
    Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structured patient interview to assess clinical outcomes in complicated urinary tract infections in the APEKS-cUTI study: pilot investigation.
    Portsmouth S; Echols R; Toyoizumi K; Tillotson G; Nagata TD
    Ther Adv Infect Dis; 2021; 8():20499361211058257. PubMed ID: 34868583
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical efficacy and safety of cefiderocol in the treatment of acute bacterial infections: A systematic review and meta-analysis of randomised controlled trials.
    Hsueh SC; Chao CM; Wang CY; Lai CC; Chen CH
    J Glob Antimicrob Resist; 2021 Mar; 24():376-382. PubMed ID: 33596476
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.
    Paul M; Daikos GL; Durante-Mangoni E; Yahav D; Carmeli Y; Benattar YD; Skiada A; Andini R; Eliakim-Raz N; Nutman A; Zusman O; Antoniadou A; Pafundi PC; Adler A; Dickstein Y; Pavleas I; Zampino R; Daitch V; Bitterman R; Zayyad H; Koppel F; Levi I; Babich T; Friberg LE; Mouton JW; Theuretzbacher U; Leibovici L
    Lancet Infect Dis; 2018 Apr; 18(4):391-400. PubMed ID: 29456043
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of cefiderocol for off-label treatment indications: A systematic review.
    Babidhan R; Lewis A; Atkins C; Jozefczyk NJ; Nemecek BD; Montepara CA; Gionfriddo MR; Zimmerman DE; Covvey JR; Guarascio AJ
    Pharmacotherapy; 2022 Jul; 42(7):549-566. PubMed ID: 35611627
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recurrent neurosurgical site infection by extensively drug-resistant
    Bavaro DF; Romanelli F; Stolfa S; Belati A; Diella L; Ronga L; Fico C; Monno L; Mosca A; Saracino A
    Infect Dis (Lond); 2021 Mar; 53(3):206-211. PubMed ID: 33295821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.